Mutual of America Capital Management LLC Trims Stock Position in ChemoCentryx, Inc. (NASDAQ:CCXI)

view original post

Mutual of America Capital Management LLC decreased its holdings in shares of ChemoCentryx, Inc. (NASDAQ:CCXIGet Rating) by 4.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 135,698 shares of the biopharmaceutical company’s stock after selling 5,902 shares during the period. Mutual of America Capital Management LLC’s holdings in ChemoCentryx were worth $3,402,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CCXI. Strs Ohio increased its position in ChemoCentryx by 8.0% during the 4th quarter. Strs Ohio now owns 13,500 shares of the biopharmaceutical company’s stock worth $491,000 after purchasing an additional 1,000 shares during the period. Paragon Capital Management Ltd acquired a new position in ChemoCentryx during the 4th quarter worth approximately $42,000. Allspring Global Investments Holdings LLC acquired a new position in ChemoCentryx during the 4th quarter worth approximately $2,896,000. State of New Jersey Common Pension Fund D acquired a new position in ChemoCentryx during the 4th quarter worth approximately $2,582,000. Finally, CWM LLC acquired a new position in ChemoCentryx during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 82.28% of the company’s stock.

Insiders Place Their Bets

In other ChemoCentryx news, Director James L. Tyree sold 3,863 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $25.66, for a total transaction of $99,124.58. Following the transaction, the director now owns 19,138 shares of the company’s stock, valued at approximately $491,081.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 8.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded ChemoCentryx from a “sell” rating to a “hold” rating in a research report on Monday. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.43.

ChemoCentryx Price Performance

Shares of NASDAQ:CCXI opened at $22.92 on Wednesday. The business’s fifty day moving average price is $23.96 and its two-hundred day moving average price is $24.55. The stock has a market cap of $1.63 billion, a PE ratio of -11.40 and a beta of 1.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.07 and a current ratio of 5.11. ChemoCentryx, Inc. has a one year low of $13.11 and a one year high of $42.16.

ChemoCentryx (NASDAQ:CCXIGet Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The company had revenue of $5.46 million for the quarter, compared to analyst estimates of $4.43 million. ChemoCentryx had a negative net margin of 514.64% and a negative return on equity of 47.24%. During the same quarter last year, the company posted ($0.43) EPS. On average, analysts forecast that ChemoCentryx, Inc. will post -1.93 EPS for the current fiscal year.

ChemoCentryx Company Profile

(Get Rating)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Read More

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXIGet Rating).

Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.